

Accelerated Digital Fundraising for Natural Botanical Medicine





WHY BOTANICAL MEDICINE?


SOM: An Untapped \$300B Market

One of the Only Markets in the World with Untapped Billion-Dollar Value "Billion-Dollar Botanicals"

MAINSTREAM DRUGS FOR

CHRONIC DISEASE

••



Masks Symptoms
No Disease Recovery



Side Effects
Contraindications




Expensive to Develop and Manufacture

BENEFITS OF NATURAL BOTANICAL MEDICINE

•••



Reverses Disease Sustained Results



No Side Effects
No Contraindications



Cheap to Develop and Manufacture

#1 OBSTACLE FOR THE BOTANICAL MEDICINE INDUSTRY:

A Lack of Funding Options








GLOBAL DIGITAL FUNDRAISING


PhytaZenica is building a digital securities exchange and fundraising platform to accelerate the globalization of natural botanical medicine.

A hybrid of crowdfunding, angel investing, and public offering, our digital platform quickly and safely injects capital into billion-dollar botanical assets to drive explosive growth in the global healthcare industry.




DIRECT DIGITAL INVESTMENTS

IN BOTANICAL ASSETS



GLOBAL

Decentralized
Equal Opportunity
Fundraising



FAST

Convenient Scalable User-Friendly




SECURE

Best-in-Class Security & Compliance

OUR DIGITAL EXCHANGE & FUNDRAISING PLATFORM

An Instant Global Public Marketplace




MICRO-MILESTONE INVESTING™:

Invest in Small Milestones for Multiple Botanical Assets

FLEXIBLE

Invest, exit, or re-invest your money instantly at any time



EFFICIENT

Diversify your portfolio: invest in multiple botanical assets



SAFE

Minimize risk: invest in small milestones (e.g., 1 clinical trial)



TYPES OF TARGET BOTANICAL ASSETS

PROFITABLE

\$1B+ Disease Markets (e.g., Cancer)

FAST APPROVAL

Approval in <5 years

CHEAP TO DEVELOP

Now: \$5M - \$50M

Later: \$50M - \$150M

TRACK RECORD

Previous


Sales Revenue

EVIDENCE


Previous

Clinical Trials


REVENUE STREAMS







Project Fundraising Commission



Equity or Token Stake in Botanical Projects



Royalty Fees From Botanical Medicine Sales



Strategic Investments in Botanical Therapies



Licensing Global Botanical Therapies

COMPETITIVE LANDSCAPE

	PhytaZenica Platform	VC Funds	Crowdfunding Platforms	Stock Exchanges	Blockchains For ICO/STO	Blockchain Exchanges
Digital (Fast)		*				
Primary Market	✓			*		Some
Secondary Market	✓	*	*		*	
Deals With Securities			Some		Some	1-2
\$300B Botanical Medicine Focus		*	*	*	*	*

COMPETITIVE ADVANTAGES




NICHE MARKET

Focus on untapped \$300B botanical medicine market



STABILITY

Digital Native Tokens
Backed By USD To
Minimize Volatility




MASS ADOPTION


Market formation, demand generation & liquidity creation

GO-TO-MARKET STRATEGY

DIGITAL SOCIAL MEDIA MARKETING



LIQUIDITY CREATION & GROWTH



DIGITAL FUNDRAISING



Primary Market
Early Stage
Fundraising



Secondary Market Instant Public Market

OUR TEAM




Jennifer Wong
Founder &
Chief Executive Officer

- >10 years of experience in business strategy, market research, competitive intelligence, marketing and sales for the healthcare and biopharmaceutical industries
- Worked closely with top global biotech and pharmaceutical companies, as well as botanical companies in the US
- Bachelor's degree in Integrative Biology from UC Berkeley



Peter Leighton
Commercial &
Marketing Strategy

- 30 years of experience in consumer products, nutrition, functional foods, nutraceuticals and biotech
- Led marketing and commercialization strategies for the successful launch of hundreds of products
- CEO at Advana Science, VP
 Marketing & Product Dev at Natrol
 (NTOL), VP at Galileo Laboratories,
 SVP Marketing at Weider Nutrition
 (WNI) and Director of Marketing at
 InterHealth Nutraceuticals



Alex Huang

Botanical Industry &

Medical Strategy Adviser

- 35 years of experience in biotech, medical devices and tech
- Founder and CEO of US botanical company LiveLeaf
- Created a model to transform active botanical compounds into targeted botanical drugs
- Patented products have gone through clinical trials with hundreds of patients
- BS in mechanical engineering, BS in electrical engineering, MS in product design from Stanford University.



Dr. Shaw ChenBotanical Medicine
Regulatory Adviser

- Worked at the FDA for >25 years approving pharmaceutical drugs and botanical drugs.
- Founder of the FDA botanical drug review team and led approval of all existing US botanical drugs.
- Approved the relaxed US botanical drug guidelines released in Dec 2016
- Will design regulatory and clinical trial strategies for PhytaZenica botanicals
- PhD from John Hopkins University;
 MD from University of Miami





Q4-2018 to Q2-2020

Team Building
Concept & Product Design
Product Development



Q3-2020 to Q1-2022

Team Building & Product Development Pre-Seed Round Fundraising Project Business Development



Q4-2021

Test Launch (Date TBD)



Q2-2022 Onwards

Product Testing & Improvement Ecosystem Growth & Stability Launch Pilot Botanical Projects



Q3-2022 Onwards

Private Sale Fundraising
Team Building & Product Development
Project Business Development




Q1-2023 Onwards

Pre-STO Sale (Optional, Dates TBD) STO Crowd Sale (Optional, Dates TBD)

PRE-SEED ROUND: \$1M

Use of Funds	Amount
Product Development	\$250K
Digital Marketing & Business Development	\$450K
Team Expansion	\$250K
Operations & Legal Expenses	\$50K





Contact Us

info@phytazenica.com